PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 11004802

[Study on recombinant BCG].

T Yamada
View original source ↗Export metadata ↓

Abstract

The progress of study on recombinant BCG was stated briefly. And then our studies on recombinant BCG were mentioned. Recombinant BCG secreting alpha antigen-fused merozoite surface protein 1 (MSP 1) was prepared and tested for its ability to control infections of Plasmodium yoelii. Result turned out it controlled the infection better than recombinant MSP 1 mixed with Freund incomplete adjuvant did. Recombinant BCG secreting excess amounts of antigen 85 complex A controlled infection of Mycobacterium leprae. Addition of recombinant BCG secreting alpha antigen-fused IL-2 to peritoneal exudate cells induced IFN-gamma resulting in killing bladder cancer cells more efficiently than parental BCG did.

Explore related subjects

Adjuvants, ImmunologicCancer VaccinesGTP PhosphohydrolasesHumansLeprosyMalaria VaccinesMerozoite Surface Protein 1Mycobacterium bovisRecombinant ProteinsTuberculosisUrinary Bladder NeoplasmsLecture

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

T Yamada. 2000. [Study on recombinant BCG].. https://pubmed.ncbi.nlm.nih.gov/11004802/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2002

Expression of the chemokine PARC mRNA in bronchoalveolar cells of patients with sarcoidosis.

BACKGROUND: Chemotactic cytokines (chemokines) have been recently implicated in the pathogenesis of interstitial lung diseases. A novel chemokine called pulmonary and activation-regulated chemokine (PARC/CCL18), which attracts lymphocytes in vitro, has been detected in the human lung. We have, therefore, investigated PARC mRNA expression in bronchoalveolar lavage fluid (BALF) cells of patients with pulmonary sarcoidosis-a disease characterised by a lymphocytic infiltrate. Further, because several immunomodulators are used in the treatment of sarcoidosis, we have determined the effects of selected drugs on PARC mRNA expression in vitro. SUBJECTS AND METHODS: BALF cells were obtained by standard bronchoalveolar lavage (BAL) from 30 patients with pulmonary sarcoidosis (S) and 16 control subjects (C). BALF cells from seven subjects were cultured in the presence of dexamethasone (Dx), cyclosporin A (CyA) and pentoxifylline (Px). PARC mRNA expression was semiquantitated by reverse-transcription polymerase chain reaction (RT-PCR) using normalisation to the expression of the beta-actin gene. RESULTS: PARC mRNA transcripts were detected in 87% of all investigated BALF samples. The expression (ODR PARC/beta-actin; median, the first to the third quartile range) was similar in both groups tested (S, 0.60 (0.50-0.95); C, 0.59 (0.36-0.93); S vs. C: P>0.05). PARC mRNA expression was not associated with the number of lymphocytes in bronchoalveolar space. PARC mRNA expression was significantly suppressed by Dx (P=0.02); CyA and Px showed a moderate inhibitory effect which did not attain significance. CONCLUSION: mRNA for the chemokine PARC is expressed in the lower respiratory tract in both healthy subjects and patients with pulmonary sarcoidosis. Out of the three immunomodulatory drugs tested, Dx downregulates PARC mRNA expression in BALF cells in vitro.

Adjuvants, Immunologic↗
PubMed2002

Peptide immunomodulators versus infection; an analysis.

A disease gets manifested only when the host immune system is not strong enough to fight off the infective agents. A number of small peptides both from natural and synthetic origin are found to be capable of modulating the immune response. While immune adjuvants are known to strengthen the immune response and help the host not to give way to the pathogens thereby preventing their establishment, the immunosuppressors are found useful in autoimmune conditions as well as in facilitating the organ transplants. Recent understanding of immune network, however, reveals its cross connectivity with the endocrine and central nervous systems as well. Thus, the inhibition and control of disease by planned restoration of homeostatis in these systems through immunomodulation is also possible.

Adjuvants, Immunologic↗